Without considering a stock's valuation, no investment decision can be efficient. The company topped consensus revenue estimates three times over this period. Over the last four quarters, Moderna surpassed consensus EPS estimates two times. EPS of $3.61 for the same period compares with $11.29 a year ago.Ĭompared to the Zacks Consensus Estimate of $5.09 billion, the reported revenues represent a surprise of -0.04%. Moderna reported revenues of $5.08 billion in the last reported quarter, representing a year-over-year change of -29.5%. Last Reported Results and Surprise History For the current and next fiscal years, $7.38 billion and $7 billion estimates indicate -61.7% and -5.1% changes, respectively. Therefore, knowing a company's potential revenue growth is crucial.įor Moderna, the consensus sales estimate for the current quarter of $1.15 billion indicates a year-over-year change of -81%. ![]() It's almost impossible for a company to grow its earnings without growing its revenue for long periods. ![]() This estimate has changed -246.3% over the last 30 days.ġ2-month consensus EPS estimate for MRNA _12MonthEPSChartUrlĮven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. The consensus earnings estimate of -$1.71 for the current fiscal year indicates a year-over-year change of -108.5%. Over the last 30 days, the Zacks Consensus Estimate has changed -112.3%. Moderna is expected to post a loss of $1.42 per share for the current quarter, representing a year-over-year change of -116.6%. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. When earnings estimates for a company go up, the fair value for its stock goes up as well. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. The key question now is: What could be the stock's future direction?Īlthough media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. ![]() ![]() During this period, the Zacks Medical - Biomedical and Genetics industry, which Moderna falls in, has lost 5.3%. Over the past month, shares of this biotechnology company have returned -22.2%, compared to the Zacks S&P 500 composite's -3.9% change. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Moderna (MRNA) is one of the stocks most watched by visitors lately.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |